Results for the substance beclomethasone formoterol glycopyrronium bromide

Beclometasone + formoterol + glycopyrronium bromide is a triple combination used in the treatment of severe chronic obstructive pulmonary disease (COPD). Beclometasone reduces inflammation, formoterol relaxes the smooth muscles of the airways, and glycopyrronium, an anticholinergic, prevents bronchial constriction.

This combination is administered as an inhaler, usually once or twice daily, depending on disease severity. It is indicated for patients who do not respond adequately to dual therapies and require better symptom control.

Common side effects include dry mouth, throat irritation, tremors, and headache. In rare cases, severe adverse reactions such as paradoxical bronchospasm, urinary retention, or cardiac arrhythmias may occur. Regular monitoring of the patient's condition is essential to ensure treatment efficacy and safety.

Beclometasone + formoterol + glycopyrronium bromide is an advanced therapeutic option for patients with severe COPD, contributing to improved lung function and quality of life.